Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
LLY logo

Lilly's Incretin Duo Mounjaro and Zepbound Drive 56% of Total Revenue

LLY10-KFiling Date: 2/12/2026
Eli Lilly and Company
Description

What this story covers

Eli Lilly’s 2025 10-K reveals a company transformed by its cardiometabolic portfolio, with Mounjaro and Zepbound driving 56% of revenue. Despite pricing pressures and legal challenges, Lilly is aggressively expanding manufacturing and R&D to sustain its global leadership.

Story snapshot

CompanyEli Lilly and Company
TickerLLY
VariantStandard detailed
Duration12:05
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000059478-26-000013
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in